title: [Four-week repeated dose oral toxicity study of BMY-28100 in juvenile beagle dogs].
abstract: Three groups, each consisting of 3 male and 3 female juvenile beagle dogs, were orally given BMY-28100 for 4 weeks at dose levels of 50, 160 and 500 mg/kg/day, respectively. Additionally, one male and one female dogs were added to each of the control and high dose groups in order to examine the recovery, and observed for 4 weeks after withdrawal of BMY-28100. The results obtained are summarized as follows: 1. BMY-28100 provoked an increased incidence of emesis in the 500 mg/kg group during the treatment period. 2. BMY-28100 sporadically brought distention of the cecum containing considerable amounts of contents in dogs sacrificed after the 4-week administration period. However, no macroscopic or microscopic changes were observed in the cecum itself after removal of the contents. In the 500 mg/kg group, hypocellularity in the sternum bone marrow was observed in a male and a female, and thymic atrophy in a male. 3. No changes ascribed to BMY-28100 treatment were detected after the 4-week recovery period. Based upon these results, the no-effect dose level of BMY-28100 was estimated to be 160 mg/kg/day, except for effects on the cecum.
authors.affiliation: Fuji Life Science Incorporated.
authors.forename: N
authors.initials: N
authors.lastname: Funahashi
authors.forename: N
authors.initials: N
authors.lastname: Shimizu
authors.forename: H
authors.initials: H
authors.lastname: Mori
authors.forename: Y
authors.initials: Y
authors.lastname: Akie
authors.forename: Y
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Watanabe
authors.forename: S
authors.initials: S
authors.lastname: Ishizuka
authors.forename: K
authors.initials: K
authors.lastname: Nagasawa
authors.forename: A
authors.initials: A
authors.lastname: Kotobuki
mesh_terms: D000284:Administration, Oral; D000367:Age Factors; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D002432:Cecum / Q000187:drug effects; D002511:Cephalosporins / Q000008:administration & dosage / Q000633:toxicity*; D004285:Dogs; D005260:Female; D006403:Hematologic Tests; D008297:Male; D013950:Thymus Gland / Q000187:drug effects; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced; D000097670:Cefprozil
chemical_list: D002511:Cephalosporins; D000097670:Cefprozil